New drug cocktail aims to boost breast cancer treatment
NCT ID NCT06637306
First seen May 15, 2026 · Last updated May 24, 2026 · Updated 1 time
Summary
This early-stage trial tests adding dupilumab (a drug for allergies and asthma) to standard chemotherapy and immunotherapy for people with locally advanced triple-negative breast cancer. The main goal is to see if the combination is safe and does not cause severe immune-related side effects. About 15 participants will receive the treatment before surgery, and researchers will also check how well it shrinks tumors.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for TNBC, TRIPLE NEGATIVE BREAST CANCER are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Mount Sinai Health System
RECRUITINGNew York, New York, 10029, United States
Contact Email: •••••@•••••
Contact
Conditions
Explore the condition pages connected to this study.